Clinical impact of IGLV3-21^R110 according to IGHV and epigenetic classifications. (A) Comparison of TTFT among patients with CLL stratified according to IGHV status and presence or absence of IGLV3-21^R110. (B) OS of patients with CLL according to IGHV status and presence or absence of IGLV3-21^R110. (C) Multivariate analysis of TTFT (top) and OS (bottom) integrating IGHV status, stereotype subset 2, and IGLV3-21^R110. (D) Comparison of TTFT among patients with CLL grouped according to epigenetic classification. (E) Comparison of TTFT of CLL patients classified according to epigenetic subtype and presence of IGLV3-21^R110. Note that i-CLL cases were divided according to presence or absence of R110 mutation. (F) Multivariate analysis of TTFT integrating epigenetic subtype (m-CLL, i-CLL, or n-CLL), stereotype subset 2, and IGLV3-21^R110. (G) Comparison of OS among patients classified according to epigenetic subtype. (H) Same as panel G but dividing i-CLL cases according to presence or absence of IGLV3-21^R110. (I) Multivariate analysis of OS integrating epigenetic subtype, stereotype subset 2, and IGLV3-21^R110. (J) Bar plot showing relationship between epigenetic subtype, IGHV mutational status, stereotype subset 2, and presence of IGLV3-21^R110. N comp. events, number of competing events for TTFT.